Clinical Trials Logo

Filter by:
NCT ID: NCT05109286 Enrolling by invitation - Clinical trials for People With Predominantly Sedentary Work

A Controlled Trial to Evaluate the Benefits of CrossFit in People Who Work Predominantly in a Sedentary Manner.

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

People who predominantly sit down often suffer from spinal complaints. This is mainly caused or intensified by a lack of exercise and a shortened posterior muscle chain. This study aims to investigate whether CrossFit can improve physical deficits, reduce pain, and improve quality of life. For this purpose, 30 test persons should take part in regular CrossFit training twice a week over one year. In addition, as a control group, 30 persons are also observed who exercise according to their ideas.

NCT ID: NCT05076617 Enrolling by invitation - Clinical trials for Stereotypical Prolonged Seizures

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Start date: February 3, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

NCT ID: NCT05061719 Enrolling by invitation - Clinical trials for Major Depressive Disorder

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Start date: October 8, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label, fixed dose, 26 week study of patients with MDD. Eligible patients from the lead-in studies will enter the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1), at which point patient eligibility will be assessed and informed consent obtained.

NCT ID: NCT05041309 Enrolling by invitation - Clinical trials for Solid and Hematological Malignancies

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Start date: December 15, 2021
Phase: Phase 2
Study type: Interventional

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored interventional studies.

NCT ID: NCT05023590 Enrolling by invitation - Atrial Fibrillation Clinical Trials

Atrial Fibrillation Registry 2017

Start date: February 22, 2017
Phase: N/A
Study type: Interventional

Monocentric, prospective, randomized trial of cardiac surgical arrhythmia using endocardial radiofrequency atrial ablation compared with a cryo ablation system in the setting of cardiac surgery.

NCT ID: NCT04976322 Enrolling by invitation - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Start date: July 27, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

NCT ID: NCT04957719 Enrolling by invitation - Clinical trials for Acute Myocardial Infarction

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

SOS-AMI
Start date: August 14, 2021
Phase: Phase 3
Study type: Interventional

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.

NCT ID: NCT04881825 Enrolling by invitation - Clinical trials for Short Bowel Syndrome

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

EASE SBS 3
Start date: June 16, 2021
Phase: Phase 3
Study type: Interventional

This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.

NCT ID: NCT04862286 Enrolling by invitation - Psoriasis Clinical Trials

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

OptIMMize-2
Start date: July 24, 2021
Phase: Phase 3
Study type: Interventional

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who completed the study M19-977. Risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). A maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide. Participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are followed up for safety for 20 weeks after last dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

NCT ID: NCT04856410 Enrolling by invitation - Clinical trials for Cognitive Performance

Effects of Long-Duration Spaceflight on General and Spatial Cognition and Its Neural Basis

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

This study investigates the effects of extended-duration spaceflight (12-month International Space Station missions) on general cognitive performance (measured with the Cognition test battery), spatial cognition, structural and functional brain changes in general, and hippocampal plasticity more specifically relative to the shorter 6-month and 2-month missions.